Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (261-270 of 477) with videos related to

Pageof 48
Sort By:
The Journal of Rheumatology|October 6, 2005
Challenges and progress in adverse event ascertainment and reporting in clinical trialsMarissa N D Lassere, Kent R Johnson, Thasia G Woodworth, et al.
Rheumatology (Oxford, England)|May 25, 2023
Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohortAbeer Ghuman, Dinesh Khanna, Celia J F Lin, et al.
Arthritis and Rheumatism|October 1, 2009
Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritisChristina Charles-Schoeman, Junji Watanabe, Yuen Yin Lee, et al.
Expert Opinion on Drug Safety|October 21, 2011
Comparative risks of non-prescription analgesics: a structured topic review and research prioritiesEric J Lavonas, James F Fries, Daniel E Furst, et al.
ACR Open Rheumatology|March 11, 2025
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic SclerosisBarbara White, Daniel E Furst, Tracy M Frech, et al.
The Lancet. Rheumatology|January 12, 2026
Isolated muscular tuberculosis with secondary haemophagocytic lymphohistiocytosisWeijin Zhang, Guangzhou Du, Shaoyu Zheng, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 9, 2020
ReplyRobert Spiera, Lorinda Chung, Tracy Frech, et al.
Biochemistry and Biophysics Reports|May 25, 2026
Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseasesShaoqi Chen, Yu Fan, Miaotong Su, et al.
Rheumatology (Oxford, England)|October 5, 2010
Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trialsMahsa Nashid, Puja P Khanna, Daniel E Furst, et al.
Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Pageof 48

Showing results (261-270 of 477) with videos related to

Sort By:
Pageof 48
The Journal of Rheumatology|October 6, 2005
Challenges and progress in adverse event ascertainment and reporting in clinical trialsMarissa N D Lassere, Kent R Johnson, Thasia G Woodworth, et al.
Rheumatology (Oxford, England)|May 25, 2023
Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohortAbeer Ghuman, Dinesh Khanna, Celia J F Lin, et al.
Arthritis and Rheumatism|October 1, 2009
Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritisChristina Charles-Schoeman, Junji Watanabe, Yuen Yin Lee, et al.
Expert Opinion on Drug Safety|October 21, 2011
Comparative risks of non-prescription analgesics: a structured topic review and research prioritiesEric J Lavonas, James F Fries, Daniel E Furst, et al.
ACR Open Rheumatology|March 11, 2025
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic SclerosisBarbara White, Daniel E Furst, Tracy M Frech, et al.
The Lancet. Rheumatology|January 12, 2026
Isolated muscular tuberculosis with secondary haemophagocytic lymphohistiocytosisWeijin Zhang, Guangzhou Du, Shaoyu Zheng, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 9, 2020
ReplyRobert Spiera, Lorinda Chung, Tracy Frech, et al.
Biochemistry and Biophysics Reports|May 25, 2026
Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseasesShaoqi Chen, Yu Fan, Miaotong Su, et al.
Rheumatology (Oxford, England)|October 5, 2010
Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trialsMahsa Nashid, Puja P Khanna, Daniel E Furst, et al.
Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Pageof 48